New Simulation Determines Max Cost for Cost-effective Health Treatments
Health care costs continue to skyrocket in the US but those costs don’t necessarily translate into better population health. Recently, [...]
Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States
Cost-effectiveness analysis is an important tool for informing treatment coverage and pricing decisions. However, there is no consensus on whether [...]
Controlling Spending In A Fee-For-Service System
The US has the highest priced healthcare on the globe, yet mechanisms used by other countries to set and update [...]
CMS expects MA, Part D payments to grow by nearly 3% in 2022
According to an advanced rate notice, the Trump administration expects Medicare Advantage (MA) and Part D payments to rise by [...]
Study Finds Remdesivir Does Little to Prevent COVID-19 Deaths
The Food and Drug Administration’s decision to grant a full approval to Gilead Sciences Inc.’s Veklury (remdesivir) is raising questions [...]
CMS Finalizes Rule Requiring Payers to Post Negotiated Rates, Cost-sharing Data
The Centers for Medicare & Medicaid Services (CMS) finalized a rule requiring private insurers to provide members with upfront prices [...]
The Value of Detailed Clinical Trial Simulations for Rare Diseases
In this latest blog, Cytel statistician Ursula Garczarek discusses the contentious topic of measuring treatment effect during rare disease trials [...]
[E-Book] Representation and diversity in clinical trials
As clinical trials are the gold standard for evidence-based medicine, it is essential for researchers to be as inclusive as [...]
Make Connections at Virtual ISPOR Europe 2020
Be sure to register now for Virtual ISPOR Europe 2020, where you will have numerous opportunities to connect with like-minded individuals [...]
Redbird RWE Develops System Making RWE Regulations More Navigable
Too much precious time is lost trying to navigate the complex and often convoluted landscape of real world evidence regulations. [...]
The Good, Bad, and Ugly of Advisory Boards
Medical Minds has a very simple philosophy when it comes to advisory boards: clearly define and agree on the objective; [...]
Election What-ifs for US Healthcare
After the economy, healthcare is the number one concern in the minds of many voters. Voters want to know how [...]
How ICER Assessments Affects Market Dynamics and Patient Access
Much research has been done on how ICER evaluations influence payer decision making. However, less is known about the effect [...]
ICER Names Leigh Purvis to Governance Board and Dr. Mark McClellan to Advisory Board
Leigh Purvis, MPA, Director of Health Care Costs and Access in AARP's Public Policy Institute, has been elected to the [...]
[Podcast] A Prescription for Fair Drug Pricing
ICER has announced the launch of a new podcast series entitled “A Prescription for Fair Drug Pricing.” In this series [...]
Incentivizing Novel Antibiotic Development–Netflix-Style
Drug makers have been increasingly disincentivized from developing novel antibiotics due to higher development costs and antibiotic stewardship programs, resulting [...]
HTA and Affordability for Innovative Therapies in Germany
A major challenge facing both HTA authorities and manufacturers is integrating new and innovative treatments into the healthcare system. A [...]
Bringing Value-Based Insurance Design to Oncology
Although the oncology field has been increasingly adopting value-based insurance designs, much work yet remains. For decades, the traditional dogma [...]
JMCP’s Call to Action in Addressing Racial Disparities in Medication Use
In a recently published article, the editorial team at 'Journal of Managed Care + Specialty Pharmacy' (JMCP) raised the question [...]
Takeda Partners With Seqster on Patient-centric Data
Seqster, a San Diego-based health technology firm, developed a platform to securely collate and store patient data such as electronic [...]
Milestones in managed care pharmacy
There have been major achievements in managed care pharmacy’s short 50-year history. Significant milestones include establishment of the pharmacy benefit [...]
FDA and Industry Set Priorities Through Prescription Drug User Fee Act (PDUFA) Reauthorization
The FDA first began the Prescription Drug User Fee Act (PDUFA) reauthorization process in July. Now the agency has released [...]
FDA Decision Alerts for AYVAKIT™ (avapritinib) and IBRANCE (palbociclib)
Blueprint Medicines Corporation’s AYVAKIT (avapritinib) was approved for adult patients with a specific type of unresectable or metastatic gastrointestinal stromal [...]
Generating Insights from RWD: Opportunities for Small and Mid-sized Biopharma
Optum possesses a robust range of real-world data (RWD) assets that afford small and mid-sized biopharma the unique opportunity to [...]
[Podcast] Where Value-Based Payments and Behavioral Health Intersect
Tune in to this healthcare podcast featuring Don Fowls, MD, president of Don Fowls and Associates, and past president of [...]